Dean Foundation for Health, Research & Education

Middleton, Wisconsin 53562

0 studies enrolling now · 9 studies all time

What they study most

Alzheimer's Disease, Depression, Generalized Anxiety Disorder, Major Depressive Disorder

Studies at this site

• A Paroxetine- and Placebo-Controlled Study of 50 mg/Day and 100 mg/Day of EB-1010 Among Outpatients With Major Depressive Disorder Who Have Responded Inadequately to Prior Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs) — Completed
• Study of Pexacerfont (BMS-562086) in the Treatment of Outpatients With Generalized Anxiety Disorder — Completed
• A Phase II, Multicenter, Double Blind, Placebo-Controlled Safety, Tolerability Study of BMS-708163 in Patients With Mild to Moderate Alzheimer's Disease — Completed
• A Multicenter, Double Blind, Placebo-Controlled, Safety and Tolerability Study of BMS-708163 in Patients With Prodromal Alzheimer's Disease — Stopped early
• Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression — Completed
• Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression — Completed
• Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression — Stopped early
• A Study of Aripiprazole in Patients With Major Depressive Disorder — Completed
• Study of BMS-562086 in the Treatment of Outpatients With Major Depressive Disorder — Completed